CERNA3:competing endogenous lncRNA 3 for miR-645
LncRNA CTA is an essential regulator in DOX-induced (doxorubicin) osteosarcoma cell apoptosis, and the lncRNA CTA-miR-210 interaction plays an important role in reducing osteosarcoma chemoresistance . Overexpression of lncRNA CTA markedly enhances DOX-induced apoptosis and inhibition of proliferation in osteosarcoma cells, MG63 and Saos-2 cells. Moreover, lncRNA CTA exerts a synergic effect with DOX in increasing the levels of Caspase 3 and in decreasing the levels of Bcl-2 and in growth inhibition of osteosarcoma cells in nude mice .
Low expression of lncRNA CTA is significantly associated with the advanced clinical stage, tumor size and the malignant progression of osteosarcoma, and patients with low lncRNA CTA expression show a worse prognosis when compared with those with high level of lncRNA CTA .
Chronic exposure to DOX induces significant downregulation of CTA in osteosarcoma MG63/DOX cells compared with their parental cells, and bioinformatic analysis shows that lncRNA CTA is a direct target of miR-21 .
CTA's expression is significantly decreased in osteosarcoma tumor tissues compared with adjacent tissues .
>XR_001745918.1 PREDICTED: Homo sapiens uncharacterized LOC105375847 (LOC105375847), transcript variant X1, ncRNA
Labs working on this lncRNA
- Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
- Wang Z, Liu Z, Wu S. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget. 2017 May 9;8(19):31465-31477.